| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 210.4 | 159.9 | 165.4 |
| Other income | 2.6 | 1.0 | 2.0 |
| Total income | 213.1 | 160.9 | 167.4 |
| Profit before exceptional items & tax | 11.2 | 14.0 | 7.3 |
| Profit before tax | 11.2 | 14.0 | 7.3 |
| Net profit | 10.8 | 10.5 | 6.0 |
| Operating margin | 5.3% | 8.7% | 4.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +80.00% |
|---|---|
| Net profit, quarter on quarter | +2.90% |
| Revenue, year on year | +27.20% |
BSE results filing, NSE: FREDUN. Figures extracted from the filing.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,360.90
- Market cap
- ₹1,944 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 44.4×Sector 50.4×
- Promoter holding
- 44.57%+0.40% QoQ
- FII holding
- 1.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 3,61,599 equity shares following the conversion of 1,20,533 warrants. This allotment was executed at an issue price of Rs. 1,250 per warrant.
- Value
- ₹15.07 Cr
Fredun Pharmaceuticals Acquisition Worth ₹300 Cr
Fredun Pharmaceuticals acquired a 26% stake in ₹300 Crore-valued Goodman Vetcare, a dedicated pet pharmacy chain. Plans target PAN-India expansion with ~₹100 Cr revenue by FY31.
- Value
- ₹300.0 Cr
- new pet pharmacy stores planned
- 8.0 stores
Fredun Pharmaceuticals Board Meeting Outcome
Fredun Pharmaceuticals allotted 2,71,200 equity shares following the conversion of 90,400 warrants. The board approved the issuance, raising Rs 11.3 Crore in total consideration.
- Value
- ₹11.30 Cr
Fredun Pharmaceuticals Business Update
Fredun Pharmaceuticals announced expansion of its Furlicks pet wellness range from 6 to 22 SKUs. The press release signals accelerated growth in the pet wellness segment.
Fredun Pharmaceuticals Acquisition
Fredun Pharmaceuticals acquires pet-wellness brand Furlicks from USV and Wellbeing Nutrition. The deal marks strategic entry into India's pet-wellness market with plans to launch 44 new SKUs.
Fredun Pharmaceuticals Product Launch
Fredun Pharmaceuticals launched PAWTALKS, a digital knowledge platform for pet and animal healthcare. Initially debuting on YouTube and Instagram, it connects veterinary experts with pet owners.